NASDAQ:ADAG - Nasdaq - US0053291078 - ADR - Currency: USD
NASDAQ:ADAG (3/7/2025, 8:03:31 PM)
2.03
-0.07 (-3.33%)
The current stock price of ADAG is 2.03 USD. In the past month the price increased by 14.08%. In the past year, price decreased by -28.01%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 174 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
ADAGENE INC-ADR
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
Suzhou JIANGSU 215123 CN
CEO: Peter (Peizhi) Luo
Employees: 174
Company Website: https://www.adagene.com/
Investor Relations: http://www.investor.adagene.com/
Phone: 8651287773632
The current stock price of ADAG is 2.03 USD. The price decreased by -3.33% in the last trading session.
The exchange symbol of ADAGENE INC-ADR is ADAG and it is listed on the Nasdaq exchange.
ADAG stock is listed on the Nasdaq exchange.
9 analysts have analysed ADAG and the average price target is 10.31 USD. This implies a price increase of 407.66% is expected in the next year compared to the current price of 2.03. Check the ADAGENE INC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ADAGENE INC-ADR (ADAG) has a market capitalization of 89.87M USD. This makes ADAG a Micro Cap stock.
ADAGENE INC-ADR (ADAG) currently has 174 employees.
ADAGENE INC-ADR (ADAG) has a support level at 2.02 and a resistance level at 2.07. Check the full technical report for a detailed analysis of ADAG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ADAG does not pay a dividend.
ADAGENE INC-ADR (ADAG) will report earnings on 2025-03-27, after the market close.
ADAGENE INC-ADR (ADAG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).
The outstanding short interest for ADAGENE INC-ADR (ADAG) is 0.14% of its float. Check the ownership tab for more information on the ADAG short interest.
ChartMill assigns a technical rating of 4 / 10 to ADAG. When comparing the yearly performance of all stocks, ADAG is a bad performer in the overall market: 76.95% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ADAG. ADAG has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ADAG reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 14.54% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -31.6% | ||
ROE | -56.28% | ||
Debt/Equity | 0.15 |
ChartMill assigns a Buy % Consensus number of 78% to ADAG. The Buy consensus is the average rating of analysts ratings from 9 analysts.